Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Adjunctive treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
8
United States
3
China
3
Hong Kong
3
Japan
2
New Zealand
2
Georgia
2
Canada
2
Malaysia
2
Korea, Republic of
2
Argentina
2
Taiwan
2
Russia
2
European Union
1
Cyprus
1
Ecuador
1
Portugal
1
Brazil
1
Norway
1
Spain
1
Ukraine
1
Israel
1
Austria
1
Peru
1
Germany
1
Slovenia
1
Australia
1
Mexico
1
Poland
1
South Africa
1
Singapore
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) | |
US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patien...
Dosage: TABLET;ORAL
15
United States
3
China
3
Hong Kong
3
Japan
3
European Union
2
New Zealand
2
Georgia
2
Canada
2
Malaysia
2
Korea, Republic of
2
Argentina
2
Taiwan
2
Russia
1
Cyprus
1
Ecuador
1
Portugal
1
Brazil
1
Norway
1
Spain
1
Ukraine
1
Israel
1
Austria
1
Peru
1
Germany
1
Slovenia
1
Australia
1
Mexico
1
Poland
1
South Africa
1
Singapore
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8034375 (Pediatric) | BRISTOL MYERS SQUIBB CO | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Jun 6, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9101660 | TAKEDA PHARMS USA | Solid preparation |
Jan, 2027
(3 years from now) |
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 August, 2005
Treatment: NA
Dosage: TABLET;ORAL
4
Japan
2
New Zealand
2
Korea, Republic of
1
Cyprus
1
China
1
Portugal
1
Brazil
1
Canada
1
Norway
1
Spain
1
Hong Kong
1
Ukraine
1
Israel
1
United States
1
Costa Rica
1
Slovenia
1
Morocco
1
Australia
1
Mexico
1
South Africa
1
Poland
1
Russia
1
Colombia
1
Denmark
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8008338 | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8008338 (Pediatric) | ALLERGAN | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2027
(4 years from now) |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7905352 | IMPAX | Kits containing medicine injection devices and containers |
Apr, 2027
(3 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7863287 | GLAXOSMITHKLINE | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
Feb, 2027
(3 years from now) |
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7811254 | MERIDIAN MEDCL | Autoinjector with needle depth adapter |
Aug, 2027
(4 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 29 June, 2010
Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes
Dosage: INJECTABLE;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(3 years from now) |
Drugs and Companies using RETAPAMULIN ingredient
Market Authorisation Date: 12 April, 2007
Treatment: NA
Dosage: OINTMENT;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(4 years from now) |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) | |
US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(3 years from now) |
Drugs and Companies using FLORBETAPIR F-18 ingredient
Market Authorisation Date: 06 April, 2012
Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
5
United States
3
European Union
2
Cyprus
2
RS
2
Portugal
2
Norway
2
Spain
2
Croatia
2
Hungary
2
Slovenia
2
Poland
2
Denmark
1
New Zealand
1
Ecuador
1
China
1
Canada
1
Brazil
1
EA
1
Korea, Republic of
1
Japan
1
Lithuania
1
Ukraine
1
Guatemala
1
Israel
1
Costa Rica
1
Austria
1
Australia
1
Mexico
1
South Africa
1
Taiwan
1
Singapore
1
Luxembourg
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7488827 | GLAXOSMITHKLINE | Muscarinic acetylcholine receptor antagonists |
Dec, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8511304 | GLAXOSMITHKLINE | Medicament dispenser |
Jun, 2027
(4 years from now) | |
US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Jun 9, 2022 |
Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.
Dosage: POWDER;INHALATION
25
United States
18
European Union
9
Japan
7
Spain
7
Australia
7
United Kingdom
6
Cyprus
6
China
6
Portugal
6
Canada
6
Hong Kong
6
Denmark
5
Brazil
5
Norway
5
Mexico
5
Poland
5
South Africa
4
Korea, Republic of
3
New Zealand
3
Israel
3
Hungary
3
Singapore
2
Croatia
2
EA
2
Slovenia
1
Ecuador
1
Uruguay
1
Netherlands
1
Malaysia
1
Luxembourg
1
Lithuania
1
Ukraine
1
Peru
1
Argentina
1
Morocco
1
Taiwan
1
Colombia
1
AP
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7553863 | PAR PHARM INC | Ultrapure 4-methylpyrazole |
Jun, 2027
(4 years from now) |
Drugs and Companies using FOMEPIZOLE ingredient
Market Authorisation Date: 04 December, 1997
Treatment: NA
Dosage: INJECTABLE;INJECTION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7687516 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) | |
US7589106 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) |
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis
Dosage: INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(4 years from now) | |
US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Mar 1, 2026 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 20 August, 2014
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M (M) | Apr 30, 2024 |
Pediatric Exclusivity (PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
Market Authorisation Date: 12 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9238108 | KALEO INC | Medicament delivery device having an electronic circuit system |
Feb, 2027
(3 years from now) | |
US8206360 | KALEO INC | Devices, systems and methods for medicament delivery |
Feb, 2027
(3 years from now) | |
US9724471 | KALEO INC | Devices, systems, and methods for medicament delivery |
May, 2027
(3 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 10 August, 2012
Treatment: Method for confirming dose delivery
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(3 years from now) | |
US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(3 years from now) |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: INJECTABLE;INTRAMUSCULAR
3
United States
2
China
2
ME
2
Korea, Republic of
2
South Africa
2
Russia
2
Denmark
2
European Union
1
New Zealand
1
Ecuador
1
Uruguay
1
Portugal
1
Brazil
1
Canada
1
Norway
1
Spain
1
Croatia
1
Jordan
1
EA
1
Hong Kong
1
Japan
1
Saudi Arabia
1
Ukraine
1
Chile
1
Yugoslavia
1
Israel
1
Costa Rica
1
Austria
1
Peru
1
Germany
1
Slovenia
1
Argentina
1
Australia
1
Iceland
1
Mexico
1
Poland
1
Taiwan
1
Colombia
1
IB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(3 years from now) | |
US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(4 years from now) |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of transdermal administration of a physiologically active agent to a subject.; A method of increa...
Dosage: SOLUTION, METERED;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(4 years from now) |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Treatment: Treatment of parkinson's disease
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery ...
Dosage: FILM;BUCCAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8835501 | ACROTECH | Pharmaceutical formulations of HDAC inhibitors |
Oct, 2027
(4 years from now) |
Drugs and Companies using BELINOSTAT ingredient
Market Authorisation Date: 03 July, 2014
Treatment: NA
Dosage: POWDER;INTRAVENOUS
6
United States
2
China
2
Spain
2
EA
2
Korea, Republic of
2
Japan
2
Israel
2
Denmark
2
European Union
1
New Zealand
1
Cyprus
1
Ecuador
1
RS
1
Portugal
1
Canada
1
Brazil
1
Norway
1
Croatia
1
Hong Kong
1
Ukraine
1
Austria
1
Slovenia
1
Australia
1
Mexico
1
United Kingdom
1
Poland
1
South Africa
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8511304 | GLAXO GRP LTD | Medicament dispenser |
Jun, 2027
(4 years from now) | |
US9333310 | GLAXO GRP LTD | Medicament dispenser |
Oct, 2027
(4 years from now) | |
US8113199 | GLAXO GRP LTD | Counter for use with a medicament dispenser |
Oct, 2027
(4 years from now) |
Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bron...
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Treatment of opioid dependence; Maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(3 years from now) | |
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(3 years from now) | |
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(3 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(4 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
7
Japan
7
United States
5
EA
5
European Union
4
New Zealand
4
Israel
4
Taiwan
3
China
3
Brazil
3
Canada
3
Spain
3
Mexico
2
Peru
2
Poland
2
Singapore
2
Denmark
1
Cyprus
1
RS
1
Switzerland
1
Portugal
1
Norway
1
Malaysia
1
Croatia
1
Hong Kong
1
Korea, Republic of
1
Chile
1
Ukraine
1
Austria
1
Germany
1
Slovenia
1
Argentina
1
Australia
1
Philippines
1
South Africa
1
Colombia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(3 years from now) | |
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(3 years from now) | |
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(3 years from now) | |
US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 22, 2024 |
Pediatric Exclusivity (PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
6
Japan
5
EA
5
United States
4
New Zealand
4
Israel
4
Taiwan
4
European Union
3
Canada
3
Brazil
3
Spain
3
Mexico
2
China
2
Peru
2
Singapore
1
Cyprus
1
RS
1
Portugal
1
Norway
1
Malaysia
1
Croatia
1
Hong Kong
1
Korea, Republic of
1
Chile
1
Ukraine
1
Slovenia
1
Argentina
1
Australia
1
Philippines
1
South Africa
1
Poland
1
Colombia
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 2024-10-06
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7838552 | ALLERGAN | Compositions comprising nebivolol |
Oct, 2027
(4 years from now) |
Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 21, 2026 |
New Patient Population (NPP) | Mar 29, 2025 |
New Dosing Schedule (D) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 2025-01-21
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
5
United States
4
European Union
1
New Zealand
1
Cyprus
1
RS
1
Uruguay
1
China
1
Portugal
1
Canada
1
Brazil
1
Spain
1
Croatia
1
Jordan
1
EA
1
Chile
1
Korea, Republic of
1
Japan
1
Lithuania
1
Ukraine
1
Israel
1
Hungary
1
Peru
1
Slovenia
1
Argentina
1
Australia
1
Mexico
1
Taiwan
1
Poland
1
Singapore
1
AP
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) | |
US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 25, 2024 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 May, 2021
Treatment: NA
Dosage: EMULSION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10758616 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
US11547758 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(3 years from now) | |
US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) | |
US9364564 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(4 years from now) |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7422388 | BECTON DICKINSON CO | Applicator for coloring antiseptic |
Apr, 2027
(3 years from now) |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 14 July, 2000
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SPONGE;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7935093 | SAGE PRODS | Disinfectant delivery system and method of providing alcohol-free disinfection |
Oct, 2027
(4 years from now) |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection
Dosage: CLOTH;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7625884 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(3 years from now) | |
US7452872 (Pediatric) | VALEANT PHARMS INTL | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Feb, 2027
(3 years from now) |
Drugs and Companies using BALSALAZIDE DISODIUM ingredient
Market Authorisation Date: 18 July, 2000
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
2
United States
2
Germany
2
European Union
1
Cyprus
1
Ecuador
1
Egypt
1
RS
1
China
1
Portugal
1
Brazil
1
Canada
1
Norway
1
Spain
1
Croatia
1
EA
1
ME
1
Korea, Republic of
1
Japan
1
Ukraine
1
Austria
1
Slovenia
1
Australia
1
Mexico
1
Poland
1
South Africa
1
Colombia
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9107837 | NALPROPION | Sustained release formulation of naltrexone |
Jun, 2027
(3 years from now) | |
US8318788 | NALPROPION | Layered pharmaceutical formulations |
Nov, 2027
(4 years from now) | |
US9125868 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
US8722085 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) | |
US10307376 | NALPROPION | Methods for administering weight loss medications |
Nov, 2027
(4 years from now) |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion in a layered formulation for chronic weight m...
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7867996 (Pediatric) | AMGEN INC | γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |
Jun, 2027
(4 years from now) |
Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 April, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8362002 (Pediatric) | GENENTECH INC | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
Apr, 2027
(3 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Oct 28, 2025 |
M (M) | Jul 28, 2025 |
Orphan Drug Exclusivity (ODE) | Oct 28, 2029 |
Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10603280 | ASTELLAS | Active ingredient containing stabilised solid medicinal forms and methods for the production thereof |
Sep, 2027
(4 years from now) | |
US10206879 | ASTELLAS | Active ingredient containing stabilised solid forms and method for the production thereof |
Sep, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 6, 2020 |
ODE* (ODE*) | Mar 6, 2022 |
Orphan Drug Exclusivity (ODE) | Mar 6, 2022 |
Generating Antibiotic Incentives Now (GAIN) | Mar 6, 2027 |
Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient
NCE-1 date: 2026-03-06
Market Authorisation Date: 06 March, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9421192 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
US8642025 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8900566 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Aug, 2027
(4 years from now) |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
Market Authorisation Date: 24 July, 2015
Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus
Dosage: TABLET;ORAL
15
United States
5
European Union
3
Cyprus
3
Spain